International Association for the Study of Lung Cancer

How is lung cancer managed in different corners of the world? 🌍 Find out on May 20 during this compelling global tumor board webinar! Through multidisciplinary case discussions, we'll explore the challenges and innovations in diagnosis, treatment, and survivorship worldwide—especially in resource-limited settings. 🎟 Register now: https://bit.ly/4jmOeMx

In the latest episode of Lung Cancer Considered, Dr. Narjust Florez M.D. FASCO leads a dynamic discussion with Drs. Eric Singhi and Misty Shields on effective communication and patient education in oncology. Learn top strategies for:  ✅ First oncology visits  ✅ Resolving conflict & miscommunication  ✅ Empowering patient understanding 🎧 Listen now: https://bit.ly/TL25LCC #LungCancerConsidered #TexasLung25 #Oncology #PatientCommunication 

In this study, Heersche et al. show that biological sex affects a patient's potential to experience severe alectinib-induced toxicity. Female patients encounter more severe toxicity, which warrants more exploration in the authors' opinions. Read more here ➡️ https://bit.ly/4443TvF Niels Heersche Erasmus MC

Here, Nakagawa et al. report the final OS outcomes for the intention-to-treat population in the double-blind, placebo-controlled phase 3 RELAY study. Read More here ➡️ https://bit.ly/42EEp5J

Brain metastases are rare in patients with PM, but this retrospective study by Stalker et al. shows that clinically significant BM was most prevalent in patients exposed to IO. Patients who received chemotherapy did not show BM, despite similar mOS between groups. Read more here: https://bit.ly/4lHdnmY

Dr. Corey Langer joins host Dr. Narjust Florez M.D. FASCO on a new episode of Lung Cancer Considered to unpack key updates from the European Lung Cancer Congress 2025 held in Paris. They explore: 🧪 MARIPOSA, ORCHARD & SOHO-01 trials ⚖️ Addressing the burden of treatment toxicity 🔍 What these findings mean for clinical practice A must-listen for anyone following the latest in lung cancer care and research! 🎧 Tune in: https://bit.ly/LCC25ELCC #ELCC25 #LungCancerConsidered

This study from Tavernari et al. highlights the need to identify uncommon mutations of EGFR to inform therapeutic decisions. Given the tobacco-related molecular signatures and high tumor mutational burden associated with this subgroup, further investigation is warranted.   Learn more ➡️ https://bit.ly/42vPXrT

Kilickap et al. bring us the 5-year follow-up from the phase 3 EMPOWER-Lung 1 trial wherein pts with advanced #NSCLC w PD-L1 expression of 50% or more received cemiplimab monotherapy as a first-line treatment. Check out the outcomes here ➡️ https://bit.ly/4lEI0td

As part of the IASLC's world-language series, Dr. Alfredo Addeo hosts a conversation with Drs. Cecilia Pompili & Francesco Passiglia in Italian on a new episode of Lung Cancer Considered. The discussion focuses on: 🫁 Resectable Stage III NSCLC 💡 Newly approved treatment options Tune in for expert insights on surgical decision-making and evolving therapies in Italy. 🎧 Listen now: https://bit.ly/ItalianVTB #LungCancer #NSCLC #Oncology #LungCancerConsidered #VirtualTumorBoard

Join leading researchers as they share insights from the NCI SCALE Collaboration, a multi-site effort to improve tobacco cessation in lung cancer screening programs. 🔍 What you'll learn: ✔️ Investigational smoking cessation strategies from SCALE trials ✔️ Implementation tactics in real-world LCS settings ✔️ Best practices and next steps for integrating cessation into screening 🗓️ Don't miss this opportunity to learn from cutting-edge research: https://bit.ly/SCLEPNCI #SmokingCessation #LungCancerScreening #TobaccoControl #PublicHealth #IASLC